Shares of Kite Pharma climbed 9 percent Tuesday after receiving positive clinical trial results for a non-Hodgkin’s lymphoma treatment.
The clinical study of a drug KTE-C19 showed that 76 percent of its patients with non-Hodgkin’s Lymphoma responded to the treatment, while 47 percent showed a complete remission, the drugmaker said in a statement on Monday.
